Real-life experiences with CAR T-cell therapy with idecabtagene vicleucel (ide-cel) for triple-class exposed relapsed/refractory multiple myeloma patients.
CAR-T
Ide-cel
Myeloma
Outcome
Relapsed
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
15 Apr 2023
15 Apr 2023
Historique:
received:
19
01
2023
accepted:
07
04
2023
medline:
18
4
2023
entrez:
15
4
2023
pubmed:
16
4
2023
Statut:
epublish
Résumé
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of triple-class exposed RRMM. We report real-life experiences with the commercial use of ide-cel in RRMM patients. We performed a retrospective analysis of the first 16 triple-class exposed RRMM patients treated with ide-cel at a single academic center. We assessed toxicities, response to treatment, CAR T expansion and soluble BCMA (sBCMA) levels. We identified 16 consecutive RRMM patients treated with ide-cel between 06-10/2022. Median age was 69 years, 6 (38%) patients had high-risk cytogenetics, 3 (19%) R-ISS stage III, and 5 (31%) extramedullary disease. Median number of previous treatment lines was 6 (3-12). Manufacturing success rate was 88% (6% required second lymphapheresis, 6% received an out-of-specification product). At 3 months, the overall response rate (ORR) was 69% (44% sCR, 6% CR, 19% VGPR). Cytokine release syndrome (CRS) occurred in 15 (94%) patients (88% G1, 6% G2), immune effector-cell associated neurotoxicity syndrome (ICANS) in 1 (6% G1), febrile neutropenia in 11 (69%), and infections in 5 (31%). Prolonged hematologic toxicity occurred in 4/16 (25%) patients. Other non-hematological toxicities were elevated hepatic enzymes (38%), colitis (6%, G3) and DIC (6%, G2). Responses were more frequent in patients with higher CAR T expansion (100% vs 38%), and lack of decrease or plateau of sBCMA levels was typically observed in non-responders. We report one of the first cohorts of RRMM treated with commercial ide-cel. The ORR was 69% and safety profile was manageable, but prolonged hematologic toxicity still represents a major challenge. Responses correlated with in vivo CAR T cell expansion, underlining the need of further research to optimize CAR T expansion.
Sections du résumé
BACKGROUND
BACKGROUND
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment landscape of relapsed/refractory multiple myeloma (RRMM), leading to unprecedented responses in this patient population. Idecabtagene vicleucel (ide-cel) has been recently approved for treatment of triple-class exposed RRMM. We report real-life experiences with the commercial use of ide-cel in RRMM patients.
METHODS
METHODS
We performed a retrospective analysis of the first 16 triple-class exposed RRMM patients treated with ide-cel at a single academic center. We assessed toxicities, response to treatment, CAR T expansion and soluble BCMA (sBCMA) levels.
RESULTS
RESULTS
We identified 16 consecutive RRMM patients treated with ide-cel between 06-10/2022. Median age was 69 years, 6 (38%) patients had high-risk cytogenetics, 3 (19%) R-ISS stage III, and 5 (31%) extramedullary disease. Median number of previous treatment lines was 6 (3-12). Manufacturing success rate was 88% (6% required second lymphapheresis, 6% received an out-of-specification product). At 3 months, the overall response rate (ORR) was 69% (44% sCR, 6% CR, 19% VGPR). Cytokine release syndrome (CRS) occurred in 15 (94%) patients (88% G1, 6% G2), immune effector-cell associated neurotoxicity syndrome (ICANS) in 1 (6% G1), febrile neutropenia in 11 (69%), and infections in 5 (31%). Prolonged hematologic toxicity occurred in 4/16 (25%) patients. Other non-hematological toxicities were elevated hepatic enzymes (38%), colitis (6%, G3) and DIC (6%, G2). Responses were more frequent in patients with higher CAR T expansion (100% vs 38%), and lack of decrease or plateau of sBCMA levels was typically observed in non-responders.
CONCLUSIONS
CONCLUSIONS
We report one of the first cohorts of RRMM treated with commercial ide-cel. The ORR was 69% and safety profile was manageable, but prolonged hematologic toxicity still represents a major challenge. Responses correlated with in vivo CAR T cell expansion, underlining the need of further research to optimize CAR T expansion.
Identifiants
pubmed: 37061680
doi: 10.1186/s12885-023-10824-3
pii: 10.1186/s12885-023-10824-3
pmc: PMC10105393
doi:
Substances chimiques
idecabtagene vicleucel
8PX1X7UG4D
Receptors, Chimeric Antigen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
345Informations de copyright
© 2023. The Author(s).
Références
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Am Soc Clin Oncol Educ Book. 2021 Mar;41:1-20
pubmed: 33989023
Cancers (Basel). 2022 Jul 20;14(14):
pubmed: 35884587
Exp Hematol. 2020 Aug;88:7-14.e3
pubmed: 32673688
Leukemia. 2020 Apr;34(4):985-1005
pubmed: 32055000
Immunotherapy. 2021 Jan;13(1):5-10
pubmed: 33045890
Bone Marrow Transplant. 2022 Dec;57(12):1839-1841
pubmed: 36131002
Blood Adv. 2022 Dec 27;6(24):6109-6119
pubmed: 35939783
J Clin Oncol. 2021 Dec 10;39(35):3978-3992
pubmed: 34724386
Curr Issues Mol Biol. 2022 Mar 24;44(4):1463-1471
pubmed: 35723356
Leukemia. 2006 Sep;20(9):1467-73
pubmed: 16855634
Mediterr J Hematol Infect Dis. 2021 Jan 01;13(1):e2021012
pubmed: 33489051
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
N Engl J Med. 2023 Mar 16;388(11):1002-1014
pubmed: 36762851
Biotechnol Genet Eng Rev. 2017 Oct;33(2):190-226
pubmed: 29431047
Bone Marrow Transplant. 2021 May;56(5):1134-1143
pubmed: 33268830
Blood Cancer J. 2021 Apr 6;11(4):69
pubmed: 33824268
Leukemia. 2020 Sep;34(9):2317-2332
pubmed: 32572190
Lancet. 2020 Sep 19;396(10254):839-852
pubmed: 32888407
Cancers (Basel). 2021 Dec 02;13(23):
pubmed: 34885182
Blood Cancer J. 2021 Apr 29;11(4):84
pubmed: 33927192
N Engl J Med. 2021 Feb 25;384(8):705-716
pubmed: 33626253
Nat Rev Cancer. 2021 Mar;21(3):145-161
pubmed: 33483715
N Engl J Med. 2022 Feb 17;386(7):640-654
pubmed: 34891224
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Lancet Oncol. 2016 Aug;17(8):e328-e346
pubmed: 27511158
Nat Med. 2022 Sep;28(9):1757-1758
pubmed: 36038630
Wien Klin Wochenschr. 2021 Dec;133(23-24):1318-1325
pubmed: 34613477
Best Pract Res Clin Haematol. 2020 Mar;33(1):101141
pubmed: 32139020
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797